Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)
Venus Remedies Ltd has informed BSE regarding "Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)".11-11-2014
11-11-2014
Shareholding Pattern For September 30, 2014
Venus Remedies Ltd has informed BSE about the Shareholding Pattern as on September 30, 2014.16-10-2014
Venus forays into Singapores topical pain management market with marketing approval, patent for Trois
Venus Remedies Ltd has informed BSE regarding "Venus forays into Singapores topical pain management market with marketing approval, patent for Trois".25-09-2014
Updates
Venus Remedies Ltd has informed BSE that:"This has reference to the downgrading of external rating by CRISIL. In this regard we would like to inform that, the company had availed a major part of the term loans for its ongoing research and development activities. The company has been consequently awarded with European and other regulated geographies "GMP" certifications for its manufacturing plants. These unstinted efforts have resulted in...16-09-2014
Venus ties up with Mylan for marketing meropenem in three European countries
Venus Remedies Ltd has informed BSE regarding "Venus ties up with Mylan for marketing meropenem in three European countries".08-09-2014
Venus shake hands with TEVA Canada for an Upcoming Anti Cancer Drug
Venus Remedies Ltd has informed BSE regarding "Venus shake hands with TEVA Canada for an Upcoming Anti Cancer Drug"04-09-2014
Extension of time for holding A G M
Venus Remedies Ltd has informed BSE that under section 96(1) of the Companies Act 2013, the Registrar of Companies has granted extension of three months for holding the Annual General Meeting pertaining to financial year ended at March 31, 2014 in the light of the ongoing preparations by the Company for providing the e-voting platform to the shareholders. Now, the Annual General Meeting will be held after September 30, 2014 latest by December 31, 2014 once the e-voting platform is ready.01-09-2014
Corrected Financial Results for June 30, 2014
Venus Remedies Ltd has submitted to BSE a copy of Corrected Financial Results for the period ended June 30, 2014.01-09-2014
Updates
Venus Remedies Ltd has informed BSE that the Company has achieved yet another landmark by receiving its first marketing authorization in SWITZERLAND from Swiss drug authority (SWISSMEDIC) for Gemcitabine 200 mg & 1 g Injection through Venus Pharma GmbH. This market approval of critically important oncology drug Gemcitabine Injection will help Venus to strengthen its oncology portfolio. The company is planning to launch this product in early next...20-08-2014
Limited Review for June 30, 2014
Venus Remedies Ltd has submitted to BSE a Copy of the Limited Review Report for the period ended June 30, 2014.14-08-2014